Evidence map›Paper›PMID 39527634›Full record

ArticleeLife2024

Functional identification of soluble uric acid as an endogenous inhibitor of CD38.

Shijie Wen, Hiroshi Arakawa, Shigeru Yokoyama, Yoshiyuki Shirasaka, Haruhiro Higashida, Ikumi Tamai

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. The GPX3-VCAM1 Axis Gates Pro-Fibrotic Tubule Cell Fate in Hyperuricemic Nephropathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shijie WenFaculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-7686-5049
Hiroshi ArakawaFaculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Shigeru YokoyamaResearch Center for Child Mental Development, Kanazawa University, Kanazawa, Japan.
Yoshiyuki ShirasakaFaculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Haruhiro HigashidaResearch Center for Child Mental Development, Kanazawa University, Kanazawa, Japan.
Ikumi TamaiFaculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.ORCID https://orcid.org/0000-0003-4388-083X

Funding

Gout and Uric Acid Foundation Research Grant 2022Japan Society for the Promotion of Science KAKENHI [JP21H02641]Japan Society for the Promotion of Science KAKENHI [JP22K19372]Japan Society for the Promotion of Science KAKENHI [JP23K18181]
6 · The paper itself

Abstract

Excessive elevation or reduction of soluble uric acid (sUA) levels has been linked to some of pathological states, raising another subject that sUA at physiological levels may be essential for the maintenance of health. Yet, the fundamental physiological functions and molecular targets of sUA remain largely unknown. Using enzyme assays and in vitro and in vivo metabolic assays, we demonstrate that sUA directly inhibits the hydrolase and cyclase activities of CD38 via a reversible non-competitive mechanism, thereby limiting nicotinamide adenine dinucleotide (NAD

Indexed as

ADP-ribosyl Cyclase 1Uric AcidAnimalsHumansInflammationLipopolysaccharidesMaleMembrane GlycoproteinsMiceMice, Inbred C57BLNADPeritonitisADP-ribosyl Cyclase 1CD38 protein, humanCd38 protein, mouseLipopolysaccharidesMembrane GlycoproteinsNADUric AcidCD38gouthyperuricemiahypouricemiaimmunologyinflammationmetabolismmouseMSU crystalnicotinamide adenine dinucleotideuric aciduricase

Identifiers

PMID39527634
PMCPMC11554305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.